ST Pharm Co.Ltd (237690) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.036x

Based on the latest financial reports, ST Pharm Co.Ltd (237690) has a cash flow conversion efficiency ratio of -0.036x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-21.16 Billion ≈ $-14.34 Million USD) by net assets (₩593.00 Billion ≈ $401.87 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of ST Pharm Co.Ltd to measure how much of total assets are equity-financed.

ST Pharm Co.Ltd - Cash Flow Conversion Efficiency Trend (2015–2025)

This chart illustrates how ST Pharm Co.Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of ST Pharm Co.Ltd to evaluate the quality of earnings relative to operating cash generation.

ST Pharm Co.Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of ST Pharm Co.Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
SANDUR MANGANESE AND IRON ORES LTD NSE:SANDUMA	0.104x
Da An Gene Co Ltd of Sun Yat-Sen University SHE:002030	0.015x
Tianjin You Fa Steel Pipe Group Stock Co Ltd SHG:601686	-0.063x
Ningbo Kangqiang Electronics Co Ltd SHE:002119	0.001x
Global Industrial Co NYSE:GIC	0.020x
Collegium Pharmaceutical Inc NASDAQ:COLL	0.285x
LuxExperience B.V. NYSE:LUXE	0.091x
Guangzhou Goaland Energy Conservation Tech Co Ltd SHE:300499	0.026x

Annual Cash Flow Conversion Efficiency for ST Pharm Co.Ltd (2015–2025)

The table below shows the annual cash flow conversion efficiency of ST Pharm Co.Ltd from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see market value of ST Pharm Co.Ltd.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	₩593.00 Billion ≈ $401.87 Million	₩13.99 Billion ≈ $9.48 Million	0.024x	-89.16%
2024-12-31	₩502.99 Billion ≈ $340.87 Million	₩109.45 Billion ≈ $74.17 Million	0.218x	+6384.31%
2023-12-31	₩386.91 Billion ≈ $262.20 Million	₩1.30 Billion ≈ $879.90K	0.003x	-83.89%
2022-12-31	₩337.63 Billion ≈ $228.81 Million	₩7.03 Billion ≈ $4.76 Million	0.021x	-7.48%
2021-12-31	₩322.97 Billion ≈ $218.87 Million	₩7.27 Billion ≈ $4.93 Million	0.023x	+131.75%
2020-12-31	₩295.33 Billion ≈ $200.14 Million	₩-20.93 Billion ≈ $-14.19 Million	-0.071x	+30.09%
2019-12-31	₩300.96 Billion ≈ $203.95 Million	₩-30.52 Billion ≈ $-20.68 Million	-0.101x	-412.25%
2018-12-31	₩331.57 Billion ≈ $224.70 Million	₩10.77 Billion ≈ $7.30 Million	0.032x	-79.06%
2017-12-31	₩351.08 Billion ≈ $237.92 Million	₩54.44 Billion ≈ $36.89 Million	0.155x	-4.35%
2016-12-31	₩313.24 Billion ≈ $212.28 Million	₩50.78 Billion ≈ $34.41 Million	0.162x	-42.38%
2015-12-31	₩127.33 Billion ≈ $86.29 Million	₩35.82 Billion ≈ $24.28 Million	0.281x	--

About ST Pharm Co.Ltd

KQ:237690 Korea Pharmaceuticals

Market Cap

$1.12 Billion

₩1.65 Trillion KRW

Market Cap Rank

#8292 Global

#204 in Korea

Share Price

₩88500.00

Change (1 day)

+4.49%

52-Week Range

₩84700.00 - ₩168700.00

All Time High

₩168700.00